Yan Yu

11PUBLICATIONS

72CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyChemotherapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|Jun 22, 2026

RBM10 Deficiency Promotes Anti-PD-1 Resistance in LUAD via STING Alternative Splicing-Driven CCL7 Signaling and Macrophage Polarization.

|Mar 12, 2026

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan, Jia Zhong, Bo-Yang Sun

|Sep 18, 2025

Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.

Mingjun Xu, Yan Xu, Yingchun Man

|Jun 17, 2025

Integrating multi-omics to unveil PSMD12 as a critical gene in promoting brain metastases of lung adenocarcinoma.

Xin Li, Juxuan Zhang, Meng Zhang

|May 16, 2025

Phase I/II Study of Tifcemalimab, an Anti-B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.

Ying Cheng, Jie Wang, Yan Yu

|Feb 27, 2025

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.

Dan-Yun Ruan, Wen-Wen Huang, Yongsheng Li

Pageof 2

Frequent Collaborators

Ying Cheng

Jie Wang

Yangchun Gu

Yan Xu

Dahai Zhao

Yuan Cheng

Pasi A Jänne

David Planchard

Kunihiko Kobayashi

Chee Khoon Lee

Frequent Collaborators

Ying Cheng

Jie Wang

Yangchun Gu

Yan Xu